HDAC9 and cancer: It has been demonstrated that histone deacetylase (HDAC) is overexpressed in multiple cancers, including prostate cancer, pancreatic ductal adenocarcinoma, and breast cancer, indicating that HDAC inhibitors are promising compounds for the therapy of proliferative diseases [16–17].